Neurodegenerative Disease Market Size, Share and Growth Outlook 2026: By Indication, By Drug Class, By Route of Administration, By Distribution Channel, Companies to 2034
The global Neurodegenerative Disease Market size is forecast to increase from $67.27 Billion in 2026 to $119.97 Billion in 2034 at a CAGR of 7.5% between 2026 and 2034.
The Neurodegenerative Disease market report provides detailed analysis and outlook of Neurodegenerative Disease segments including By Indication (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Spinal Muscular Atrophy (SMA)), By Drug Class (Immunomodulators & Monoclonal Antibodies, Cholinesterase Inhibitors, Dopaminergic Drugs & Dopamine Agonists, NMDA Receptor Antagonists, Gene Therapy & Molecular Therapeutics, Interferons), By Route of Administration (Oral, Injectable / Parenteral, Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Neurodegenerative Disease Industry Overview
Expanding Therapeutic Innovation Transforming Neurodegenerative Disease Research
The neurodegenerative disease industry is experiencing significant scientific and commercial activity as pharmaceutical companies intensify efforts to develop disease-modifying therapies for conditions such as Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and other progressive neurological disorders. Advances in molecular biology, biomarker identification, genetic medicine, and neurodegeneration research are enabling more targeted therapeutic approaches aimed at addressing the underlying mechanisms of disease progression rather than solely managing symptoms. Industry participants are increasingly investing in diversified pipelines that target amyloid accumulation, tau pathology, neuroinflammation, protein aggregation, and genetic abnormalities. This broader scientific focus reflects the growing recognition that neurodegenerative diseases involve multiple biological pathways that require increasingly sophisticated treatment strategies.
Alzheimer's Drug Development Expands Beyond Traditional Amyloid Approaches
A major trend shaping the industry is the diversification of Alzheimer's disease therapeutic development beyond conventional amyloid-targeting strategies. Eli Lilly strengthened its neuroscience portfolio through a global licensing agreement with AlzeCure Pharma for ACD680, a preclinical gamma-secretase modulator designed to reduce production of toxic amyloid-beta peptides, particularly A?42, which are associated with Alzheimer's pathology. The agreement complements Lilly’s existing Alzheimer's portfolio and demonstrates continued investment in small-molecule approaches targeting amyloid biology. At the same time, the industry is increasingly exploring additional disease mechanisms. Biogen reported topline results from the Phase 2 CELIA study evaluating diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. Although the study did not achieve its primary endpoint, observed reductions in tau protein and indications of slowed cognitive decline support ongoing industry interest in addressing neurodegeneration through non-amyloid pathways.
Regulatory Momentum and Rare Disease Research Strengthening Industry Development
The neurodegenerative disease landscape is also benefiting from increased regulatory support for innovative therapies addressing serious neurological conditions. Biogen announced that Salanersen received FDA Breakthrough Therapy Designation for the treatment of spinal muscular atrophy, reflecting the growing importance of accelerated regulatory pathways in advancing therapies for rare and debilitating neurological diseases. Such designations are intended to expedite clinical development and regulatory review for therapies demonstrating meaningful potential over existing treatment options. Across the broader market, companies are increasingly integrating biomarker-driven development strategies, precision medicine approaches, and advanced clinical trial methodologies to improve therapeutic outcomes. These developments highlight the industry's commitment to expanding treatment options across both common neurodegenerative disorders and rare neurological diseases while advancing the understanding of complex disease biology through increasingly targeted research programs.
Neurodegenerative Disease Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Neurodegenerative Disease market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.. The Neurodegenerative Disease market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Neurodegenerative Disease industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Neurodegenerative Disease industry include- Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.. The Neurodegenerative Disease market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Neurodegenerative Disease Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Neurodegenerative Disease market remains one of the strongest-performing segments in the country.
The US Neurodegenerative Disease Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Neurodegenerative Disease market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Neurodegenerative Disease industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Neurodegenerative Disease markets
Canada's strong Neurodegenerative Disease sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Neurodegenerative Disease market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Neurodegenerative Disease Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Neurodegenerative Disease market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Neurodegenerative Disease population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Neurodegenerative Disease industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Neurodegenerative Disease market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Neurodegenerative Disease sales through 2034
France Neurodegenerative Disease companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Neurodegenerative Disease Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Neurodegenerative Disease distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Neurodegenerative Disease Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Neurodegenerative Disease market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Neurodegenerative Disease industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Neurodegenerative Disease industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Neurodegenerative Disease Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Neurodegenerative Disease market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Neurodegenerative Disease market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Neurodegenerative Disease Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Neurodegenerative Disease Market Segmentation
By Indication
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis (MS)
Amyotrophic Lateral Sclerosis (ALS)
Huntington’s Disease
Spinal Muscular Atrophy (SMA)
By Drug Class
Immunomodulators & Monoclonal Antibodies
Cholinesterase Inhibitors
Dopaminergic Drugs & Dopamine Agonists
NMDA Receptor Antagonists
Gene Therapy & Molecular Therapeutics
Interferons
By Route of Administration
Oral
Injectable / Parenteral
Transdermal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Pharmacies
Leading Companies in Neurodegenerative Disease Industry (2026)
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Pfizer Inc.
Johnson & Johnson
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Countries Included
The Neurodegenerative Disease market report provides detailed analysis and outlook of Neurodegenerative Disease segments including By Indication (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Spinal Muscular Atrophy (SMA)), By Drug Class (Immunomodulators & Monoclonal Antibodies, Cholinesterase Inhibitors, Dopaminergic Drugs & Dopamine Agonists, NMDA Receptor Antagonists, Gene Therapy & Molecular Therapeutics, Interferons), By Route of Administration (Oral, Injectable / Parenteral, Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Neurodegenerative Disease Industry Overview
Expanding Therapeutic Innovation Transforming Neurodegenerative Disease Research
The neurodegenerative disease industry is experiencing significant scientific and commercial activity as pharmaceutical companies intensify efforts to develop disease-modifying therapies for conditions such as Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and other progressive neurological disorders. Advances in molecular biology, biomarker identification, genetic medicine, and neurodegeneration research are enabling more targeted therapeutic approaches aimed at addressing the underlying mechanisms of disease progression rather than solely managing symptoms. Industry participants are increasingly investing in diversified pipelines that target amyloid accumulation, tau pathology, neuroinflammation, protein aggregation, and genetic abnormalities. This broader scientific focus reflects the growing recognition that neurodegenerative diseases involve multiple biological pathways that require increasingly sophisticated treatment strategies.
Alzheimer's Drug Development Expands Beyond Traditional Amyloid Approaches
A major trend shaping the industry is the diversification of Alzheimer's disease therapeutic development beyond conventional amyloid-targeting strategies. Eli Lilly strengthened its neuroscience portfolio through a global licensing agreement with AlzeCure Pharma for ACD680, a preclinical gamma-secretase modulator designed to reduce production of toxic amyloid-beta peptides, particularly A?42, which are associated with Alzheimer's pathology. The agreement complements Lilly’s existing Alzheimer's portfolio and demonstrates continued investment in small-molecule approaches targeting amyloid biology. At the same time, the industry is increasingly exploring additional disease mechanisms. Biogen reported topline results from the Phase 2 CELIA study evaluating diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. Although the study did not achieve its primary endpoint, observed reductions in tau protein and indications of slowed cognitive decline support ongoing industry interest in addressing neurodegeneration through non-amyloid pathways.
Regulatory Momentum and Rare Disease Research Strengthening Industry Development
The neurodegenerative disease landscape is also benefiting from increased regulatory support for innovative therapies addressing serious neurological conditions. Biogen announced that Salanersen received FDA Breakthrough Therapy Designation for the treatment of spinal muscular atrophy, reflecting the growing importance of accelerated regulatory pathways in advancing therapies for rare and debilitating neurological diseases. Such designations are intended to expedite clinical development and regulatory review for therapies demonstrating meaningful potential over existing treatment options. Across the broader market, companies are increasingly integrating biomarker-driven development strategies, precision medicine approaches, and advanced clinical trial methodologies to improve therapeutic outcomes. These developments highlight the industry's commitment to expanding treatment options across both common neurodegenerative disorders and rare neurological diseases while advancing the understanding of complex disease biology through increasingly targeted research programs.
Neurodegenerative Disease Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Neurodegenerative Disease market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.. The Neurodegenerative Disease market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Neurodegenerative Disease industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Neurodegenerative Disease Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Neurodegenerative Disease companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Neurodegenerative Disease markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Neurodegenerative Disease industry include- Biogen Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.. The Neurodegenerative Disease market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Neurodegenerative Disease Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Neurodegenerative Disease market remains one of the strongest-performing segments in the country.
The US Neurodegenerative Disease Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Neurodegenerative Disease market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Neurodegenerative Disease industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Neurodegenerative Disease markets
Canada's strong Neurodegenerative Disease sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Neurodegenerative Disease market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Neurodegenerative Disease Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Neurodegenerative Disease market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Neurodegenerative Disease population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Neurodegenerative Disease industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Neurodegenerative Disease market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Neurodegenerative Disease sales through 2034
France Neurodegenerative Disease companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Neurodegenerative Disease Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Neurodegenerative Disease distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Neurodegenerative Disease Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Neurodegenerative Disease market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Neurodegenerative Disease industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Neurodegenerative Disease industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Neurodegenerative Disease Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Neurodegenerative Disease market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Neurodegenerative Disease market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Neurodegenerative Disease Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Neurodegenerative Disease Market Segmentation
By Indication
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis (MS)
Amyotrophic Lateral Sclerosis (ALS)
Huntington’s Disease
Spinal Muscular Atrophy (SMA)
By Drug Class
Immunomodulators & Monoclonal Antibodies
Cholinesterase Inhibitors
Dopaminergic Drugs & Dopamine Agonists
NMDA Receptor Antagonists
Gene Therapy & Molecular Therapeutics
Interferons
By Route of Administration
Oral
Injectable / Parenteral
Transdermal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Pharmacies
Leading Companies in Neurodegenerative Disease Industry (2026)
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Pfizer Inc.
Johnson & Johnson
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Neurodegenerative Disease Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Neurodegenerative Disease Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NEURODEGENERATIVE DISEASE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Neurodegenerative Disease Markets in 2026
3.2. Global Historic and Forecast Neurodegenerative Disease Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Neurodegenerative Disease Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Neurodegenerative Disease Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Neurodegenerative Disease Value Chain
CHAPTER 4- NEURODEGENERATIVE DISEASE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Neurodegenerative Disease Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NEURODEGENERATIVE DISEASE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Indication
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis (MS)
Amyotrophic Lateral Sclerosis (ALS)
Huntington’s Disease
Spinal Muscular Atrophy (SMA)
By Drug Class
Immunomodulators & Monoclonal Antibodies
Cholinesterase Inhibitors
Dopaminergic Drugs & Dopamine Agonists
NMDA Receptor Antagonists
Gene Therapy & Molecular Therapeutics
Interferons
By Route of Administration
Oral
Injectable / Parenteral
Transdermal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Pharmacies
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Neurodegenerative Disease Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
7.5. North America Neurodegenerative Disease Market Size Outlook by Type
7.6. North America Neurodegenerative Disease Market Size Outlook by Application
7.7. North America Neurodegenerative Disease Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Neurodegenerative Disease Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Neurodegenerative Disease Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Neurodegenerative Disease Companies
CHAPTER 8- EUROPE NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Neurodegenerative Disease Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
8.5. Europe Neurodegenerative Disease Market Size Outlook by Type
8.6. Europe Neurodegenerative Disease Market Size Outlook by Application
8.7. Europe Neurodegenerative Disease Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Neurodegenerative Disease Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Neurodegenerative Disease Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Neurodegenerative Disease Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Neurodegenerative Disease Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Neurodegenerative Disease Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Neurodegenerative Disease Companies
CHAPTER 9- ASIA PACIFIC NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Neurodegenerative Disease Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Neurodegenerative Disease Market Size Outlook by Type
9.6. Asia Pacific Neurodegenerative Disease Market Size Outlook by Application
9.7. Asia Pacific Neurodegenerative Disease Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Neurodegenerative Disease Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Neurodegenerative Disease Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Neurodegenerative Disease Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Neurodegenerative Disease Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Neurodegenerative Disease Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Neurodegenerative Disease Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Neurodegenerative Disease Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
10.5. South and Central America Neurodegenerative Disease Market Size Outlook by Type
10.6. South and Central America Neurodegenerative Disease Market Size Outlook by Application
10.7. South and Central America Neurodegenerative Disease Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Neurodegenerative Disease Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Neurodegenerative Disease Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Neurodegenerative Disease Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Neurodegenerative Disease Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Type
11.6. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Application
11.7. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Neurodegenerative Disease Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Neurodegenerative Disease Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Neurodegenerative Disease Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Neurodegenerative Disease Industry
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Pfizer Inc.
Johnson & Johnson
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Neurodegenerative Disease Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Neurodegenerative Disease Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NEURODEGENERATIVE DISEASE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Neurodegenerative Disease Markets in 2026
3.2. Global Historic and Forecast Neurodegenerative Disease Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Neurodegenerative Disease Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Neurodegenerative Disease Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Neurodegenerative Disease Value Chain
CHAPTER 4- NEURODEGENERATIVE DISEASE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Neurodegenerative Disease Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NEURODEGENERATIVE DISEASE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Indication
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis (MS)
Amyotrophic Lateral Sclerosis (ALS)
Huntington’s Disease
Spinal Muscular Atrophy (SMA)
By Drug Class
Immunomodulators & Monoclonal Antibodies
Cholinesterase Inhibitors
Dopaminergic Drugs & Dopamine Agonists
NMDA Receptor Antagonists
Gene Therapy & Molecular Therapeutics
Interferons
By Route of Administration
Oral
Injectable / Parenteral
Transdermal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Pharmacies
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Neurodegenerative Disease Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
7.5. North America Neurodegenerative Disease Market Size Outlook by Type
7.6. North America Neurodegenerative Disease Market Size Outlook by Application
7.7. North America Neurodegenerative Disease Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Neurodegenerative Disease Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Neurodegenerative Disease Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Neurodegenerative Disease Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Neurodegenerative Disease Companies
CHAPTER 8- EUROPE NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Neurodegenerative Disease Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
8.5. Europe Neurodegenerative Disease Market Size Outlook by Type
8.6. Europe Neurodegenerative Disease Market Size Outlook by Application
8.7. Europe Neurodegenerative Disease Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Neurodegenerative Disease Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Neurodegenerative Disease Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Neurodegenerative Disease Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Neurodegenerative Disease Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Neurodegenerative Disease Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Neurodegenerative Disease Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Neurodegenerative Disease Companies
CHAPTER 9- ASIA PACIFIC NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Neurodegenerative Disease Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Neurodegenerative Disease Market Size Outlook by Type
9.6. Asia Pacific Neurodegenerative Disease Market Size Outlook by Application
9.7. Asia Pacific Neurodegenerative Disease Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Neurodegenerative Disease Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Neurodegenerative Disease Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Neurodegenerative Disease Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Neurodegenerative Disease Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Neurodegenerative Disease Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Neurodegenerative Disease Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Neurodegenerative Disease Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Neurodegenerative Disease Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
10.5. South and Central America Neurodegenerative Disease Market Size Outlook by Type
10.6. South and Central America Neurodegenerative Disease Market Size Outlook by Application
10.7. South and Central America Neurodegenerative Disease Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Neurodegenerative Disease Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Neurodegenerative Disease Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Neurodegenerative Disease Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Neurodegenerative Disease Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NEURODEGENERATIVE DISEASE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Neurodegenerative Disease Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Neurodegenerative Disease Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Type
11.6. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Application
11.7. Middle East and Africa Neurodegenerative Disease Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Neurodegenerative Disease Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Neurodegenerative Disease Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Neurodegenerative Disease Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Neurodegenerative Disease Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Neurodegenerative Disease Industry
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc.
Pfizer Inc.
Johnson & Johnson
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
